UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa

The New England journal of medicine, 2016-08, Vol.375 (5), p.422-434

2016

Volltextzugriff (PDF)

Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial

The Lancet (British edition), 2019-08, Vol.394 (10198), p.576-586

2019

Volltextzugriff (PDF)

Treatment of nail psoriasis: best practice recommendations from the Medical Board of the National Psoriasis Foundation

JAMA dermatology (Chicago, Ill.), 2015-01, Vol.151 (1), p.87

2015

Volltextzugriff (PDF)

Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial

Journal of the American Academy of Dermatology, 2018-01, Vol.78 (1), p.90-99.e1

2018

Volltextzugriff (PDF)

A brief guide to pustular psoriasis for primary care providers

Postgraduate medicine, 2021-04, Vol.133 (3), p.330-344

2021

Volltextzugriff (PDF)

Use of Biologic Agents in Combination with Other Therapies for the Treatment of Psoriasis

American journal of clinical dermatology, 2014-12, Vol.15 (6), p.467-478

2014

Volltextzugriff (PDF)

A series of critically challenging case scenarios in moderate to severe psoriasis: A Delphi consensus approach

Journal of the American Academy of Dermatology, 2009-07, Vol.61 (1), p.S1-S46

2009

Volltextzugriff (PDF)

Improvements in psoriasis within different body regions vary over time following treatment with ixekizumab

The Journal of dermatological treatment, 2018-05, Vol.29 (3), p.220-229

2018

Volltextzugriff (PDF)

Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study

Dermatology and therapy, 2022-02, Vol.12 (2), p.561-575

2022

Volltextzugriff (PDF)

44134 Long-Term Improvement in Difficult-To-Treat Areas and Quality of Life in Patients with Psoriasis Up to 204 Weeks Post Switch From Ustekinumab To Risankizumab

Journal of the American Academy of Dermatology, 2023-09, Vol.89 (3), p.AB190-AB190

2023

Volltextzugriff (PDF)

51109 Efficacy of deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in scalp psoriasis by baseline Psoriasis Area and Severity Index (PASI) and baseline body surface area (BSA): A subanalysis of the phase 3 clinical trial data

Journal of the American Academy of Dermatology, 2024-09, Vol.91 (3), p.AB37-AB37

2024

Volltextzugriff (PDF)

16480 Characteristics associated with progression of hidradenitis suppurativa: 2-year interim results from the HS UNITE registry

Journal of the American Academy of Dermatology, 2020-12, Vol.83 (6), p.AB65-AB65

2020

Volltextzugriff (PDF)

Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere)

JAMA dermatology (Chicago, Ill.), 2023-02, Vol.159 (2), p.182

2023

Volltextzugriff (PDF)

13877 Treatment goals of patients with psoriasis as assessed by the Patient Benefit Index: Results of a National Psoriasis Foundation survey

Journal of the American Academy of Dermatology, 2020-12, Vol.83 (6), p.AB125-AB125

2020

Volltextzugriff (PDF)

A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1

Dermatology and therapy, 2012-12, Vol.2 (1), p.1-1, Article 1

2012

Volltextzugriff (PDF)

A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2

Dermatology and therapy, 2012-12, Vol.2 (1), p.2-2, Article 2

2012

Volltextzugriff (PDF)

Efficacy of Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 (TYK2) Inhibitor, in Scalp Psoriasis by Baseline Psoriasis Area and Severity Index (PASI) and Baseline Body Surface Area (BSA): A Subanalysis of the Phase 3 Clinical Trial Data

Skin (Milwood, N.Y.), 2024-07, Vol.8 (4), p.s405

2024

Volltextzugriff (PDF)

Correlation of Physician-Assessed Psoriasis Area and Severity Index Scores With Patient-Reported Psoriasis Symptoms and Signs Diary Scores Among Patients With Moderate-to-Severe Psoriasis: Results From VOYAGE 1 and VOYAGE 2 Studies

Journal of psoriasis and psoriatic arthritis, 2019-07, Vol.4 (3), p.147-152

2019

Volltextzugriff (PDF)

Cutaneous gnathostomiasis

Journal of the American Academy of Dermatology, 1995-11, Vol.33 (5), p.825-828

1995

Volltextzugriff (PDF)

Challenges in Psoriasis Treatment: Nail, Scalp, and Palmoplantar Involvement

Advances in Psoriasis, 2020, p.343-362

2020

Volltextzugriff (PDF)

Mycosis fungoides in young patients: Clinical characteristics and outcome

Journal of the American Academy of Dermatology, 1998-05, Vol.38 (5), p.696-701

1998

Volltextzugriff (PDF)

Etanercept improves psoriatic arthritis patient-reported outcomes : Results from EDUCATE

Cutis (New York, N.Y.), 2007-04, Vol.79 (4), p.322-326

2007

Volltextzugriff (PDF)

Nail, Scalp, and Palmoplantar Psoriasis

Biologic and Systemic Agents in Dermatology, 2018, p.159-174

2018

Volltextzugriff (PDF)

Blastomycosis-like pyoderma in a man with AIDS

Journal of the American Academy of Dermatology, 1997-04, Vol.36 (4), p.633-664

1997

Volltextzugriff (PDF)

Attenuation of tumor necrosis factor-induced endothelial cell cytotoxicity and neutrophil chemiluminescence

The American review of respiratory disease, 1990-11, Vol.142 (5), p.1073-1078

1990

Volltextzugriff (PDF)

1 – 25 von 255

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(223)
Mit Volltextzugriff
(205)

Publikationsform

Sprache

Englisch
(253)
Französisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(161)
Life Sciences & Biomedicine
(145)
Humans
(93)
Biological And Medical Sciences
(61)
Male
(60)
Female
(57)
Adult
(48)
Medical Sciences
(47)
Middle Aged
(35)
Animals
(27)
General & Internal Medicine
(23)
Adolescent
(22)
Aged
(21)
Medicine, General & Internal
(19)
Treatment Outcome
(18)
Fundamental And Applied Biological Sciences. Psychology
(17)
Physical Sciences
(16)
Social Sciences
(15)
Dermatology
(14)
Psychiatry
(13)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa

Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial

Treatment of nail psoriasis: best practice recommendations from the Medical Board of the National Psoriasis Foundation

Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial

A brief guide to pustular psoriasis for primary care providers

Use of Biologic Agents in Combination with Other Therapies for the Treatment of Psoriasis

A series of critically challenging case scenarios in moderate to severe psoriasis: A Delphi consensus approach

Improvements in psoriasis within different body regions vary over time following treatment with ixekizumab

Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study

44134 Long-Term Improvement in Difficult-To-Treat Areas and Quality of Life in Patients with Psoriasis Up to 204 Weeks Post Switch From Ustekinumab To Risankizumab

51109 Efficacy of deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in scalp psoriasis by baseline Psoriasis Area and Severity Index (PASI) and baseline body surface area (BSA): A subanalysis of the phase 3 clinical trial data

16480 Characteristics associated with progression of hidradenitis suppurativa: 2-year interim results from the HS UNITE registry

Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere)

13877 Treatment goals of patients with psoriasis as assessed by the Patient Benefit Index: Results of a National Psoriasis Foundation survey

A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1

A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2

Efficacy of Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 (TYK2) Inhibitor, in Scalp Psoriasis by Baseline Psoriasis Area and Severity Index (PASI) and Baseline Body Surface Area (BSA): A Subanalysis of the Phase 3 Clinical Trial Data

Correlation of Physician-Assessed Psoriasis Area and Severity Index Scores With Patient-Reported Psoriasis Symptoms and Signs Diary Scores Among Patients With Moderate-to-Severe Psoriasis: Results From VOYAGE 1 and VOYAGE 2 Studies

Cutaneous gnathostomiasis

Challenges in Psoriasis Treatment: Nail, Scalp, and Palmoplantar Involvement

Mycosis fungoides in young patients: Clinical characteristics and outcome

Etanercept improves psoriatic arthritis patient-reported outcomes : Results from EDUCATE

Nail, Scalp, and Palmoplantar Psoriasis

Blastomycosis-like pyoderma in a man with AIDS

Attenuation of tumor necrosis factor-induced endothelial cell cytotoxicity and neutrophil chemiluminescence

Suchergebnisse filtern